NEWS
News
15 October 2026 EVENT
EpiQuil showcases its technology at UNSW Investor Showcase
EpiQuil presented its dissolving microneedle drug delivery platform at the UNSW Investor Showcase, connecting with investors and industry stakeholders and demonstrating its approach to delivering complex medicines through the skin.
July 2026 PROGRAMME
EpiQuil receives ethics approval for preclinical pharmacokinetic study
EpiQuil has received ethics approval for its preclinical pharmacokinetic study, marking an important step in evaluating its microneedle delivery platform and supporting the next phase of development.
15 October 2026 PROGRAMME
EpiQuil selected for UNSW Health10x 2026 Accelerator
EpiQuil joined the Health10x Accelerator, supporting the development and commercialisation of innovative health technologies. The programme provided valuable mentorship, industry connections and opportunities to refine our clinical development and commercialisation strategy.
Updates from EpiQuil. For media enquiries, email info@epiquil.com